Physician profile
Scott C Schmidt
NPI 1114599313
$1,264.39
in general payments reported to CMS, 2019-2025
21 companies · $768 in 2025
The $768 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.33 · 2024: $484 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $191.33 | 2025 | Korlym |
| Novo Nordisk INC | $175.20 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $164.54 | 2024-2025 | |
| Lilly USA, LLC | $110.89 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $91.55 | 2024-2025 | |
| Exact Sciences Corporation | $60.63 | 2024 | Cologuard Collection Kit |
| Abbvie INC. | $52.66 | 2025 | |
| Glaxosmithkline, LLC. | $48.56 | 2024-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.46 | 2024-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $44.65 | 2024-2025 | Zenpep |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.93 | 2024-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $41.19 | 2024-2025 | Xtampza |
| Mayne Pharma Commercial LLC | $32.40 | 2025 | |
| Hologic Sales and Service, LLC | $28.79 | 2025 | Aptima |
| Madrigal Pharmaceuticals | $26.81 | 2024 | Resmetirom |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.25 | 2025 | Id Now Instrument |
| Heartflow, INC. | $20.30 | 2024 | |
| Scilex Pharmaceuticals INC. | $17.61 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.59 | 2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $14.72 | 2025 | Breztri |
| Ultragenyx Pharmaceutical INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.